Autolus Therapeutics price target lowered to $6 from $8 at Wells Fargo

Wells Fargo lowered the firm’s price target on Autolus Therapeutics (AUTL) to $6 from $8 and keeps an Overweight rating on the shares. With Aucatzyl launch still in early phase, the firm thinks the main near-term focus is the initial SLE readout on April 23, where it believes a key factor to consider when interpreting data and comparing across datasets is existing tissue damage at baseline.